Bora Lim, Liyi Jia, Preeti K. Sudheendra, Kim M. Hirshfield. "LITESPARK-029: A phase 2, randomized, open-label study of belzutifan plus fulvestrant in participants with estrogen receptor–positive, HER2-negative unresectable locally advanced or metastatic breast cancer after progression on previous endocrine therapy.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.tps1124